600420 国药现代
已收盘 04-17 15:00:00
资讯
新帖
简况
国药现代（600420）披露为下属公司提供担保的进展公告，4月15日股价上涨1.94%
证券之星 · 04-15 22:24
国药现代（600420）披露为下属公司提供担保的进展公告，4月15日股价上涨1.94%
股市必读：国药现代（600420）4月13日收盘跌5.48%，主力净流入21.68万元
证券之星 · 04-14
股市必读：国药现代（600420）4月13日收盘跌5.48%，主力净流入21.68万元
每周股票复盘：国药现代（600420）一季度净利预盈1.26亿至1.48亿元
证券之星 · 04-12
每周股票复盘：国药现代（600420）一季度净利预盈1.26亿至1.48亿元
国药现代(600420.SH)发预减，预计第一季度归母净利润1.26亿元到1.48亿元，同比下降65.03%到58.94%
智通财经 · 04-10
国药现代(600420.SH)发预减，预计第一季度归母净利润1.26亿元到1.48亿元，同比下降65.03%到58.94%
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，4月7日股价下跌0.28%
证券之星 · 04-07
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，4月7日股价下跌0.28%
国药现代(600420.SH)：盐酸氨溴索片通过一致性评价
智通财经 · 04-03
国药现代(600420.SH)：盐酸氨溴索片通过一致性评价
国药现代(600420.SH)子公司获左卡尼汀注射液药品注册证书
智通财经 · 04-03
国药现代(600420.SH)子公司获左卡尼汀注射液药品注册证书
股市必读：国药现代年报 - 第四季度单季净利润同比增长8.78%
证券之星 · 03-30
股市必读：国药现代年报 - 第四季度单季净利润同比增长8.78%
国药现代(600420)2月28日股东户数3.59万户，较上期减少7.78%
证券之星 · 03-28
国药现代(600420)2月28日股东户数3.59万户，较上期减少7.78%
国药现代(600420.SH)发布2025年度业绩，归母净利润9.42亿元，同比下降13.11%
智通财经 · 03-27
国药现代(600420.SH)发布2025年度业绩，归母净利润9.42亿元，同比下降13.11%
国药现代拟每10股派发现金股利2元
财中社 · 03-27
国药现代拟每10股派发现金股利2元
国药现代最新公告：控股子公司签署《药品上市许可转让合同》
证券之星 · 03-24
国药现代最新公告：控股子公司签署《药品上市许可转让合同》
国药现代(600420.SH)：己酮可可碱注射液获药品注册证书
智通财经 · 03-03
国药现代(600420.SH)：己酮可可碱注射液获药品注册证书
每周股票复盘：国药现代（600420）全资孙公司获原料药上市批准
证券之星 · 03-01
每周股票复盘：国药现代（600420）全资孙公司获原料药上市批准
国药现代(600420.SH)：盐酸米那普仑获得化学原料药上市申请批准
智通财经 · 02-24
国药现代(600420.SH)：盐酸米那普仑获得化学原料药上市申请批准
国药现代最新公告：公司及下属子公司51个药品拟中选国家集采药品接续采购
证券之星 · 02-11
国药现代最新公告：公司及下属子公司51个药品拟中选国家集采药品接续采购
每周股票复盘：国药现代（600420）2025年净利降12.85%
证券之星 · 02-01
每周股票复盘：国药现代（600420）2025年净利降12.85%
国药现代发布2025年度业绩快报，盈利9.444亿元
证券之星 · 01-26
国药现代发布2025年度业绩快报，盈利9.444亿元
国药现代：公司积极推进缓控释、膜剂等创新技术平台建设
证券日报 · 01-23
国药现代：公司积极推进缓控释、膜剂等创新技术平台建设
每周股票复盘：国药现代（600420）注射用哌拉西林钠通过一致性评价
证券之星 · 01-18
每周股票复盘：国药现代（600420）注射用哌拉西林钠通过一致性评价
公司概况
公司名称：
上海现代制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-06-16
主营业务：
上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是6-APA、7-ACA、D-7ACA、青霉素工业钾盐、头孢曲松钠粗盐、氨苄西林酸。在制剂产品方面，根据米内网数据库显示，公司头孢呋辛酯片、注射用甲泼尼龙琥珀酸钠国内市场占有率稳居行业第一；头孢克肟颗粒市场份额进一步提升，展现出良好的增长态势；硝苯地平控释片、盐酸米那普仑片市场占有率稳居仿制药企业第一。
发行价格：
8.08
{"stockData":{"symbol":"600420","market":"SH","secType":"STK","nameCN":"国药现代","latestPrice":9.81,"timestamp":1776409200000,"preClose":9.92,"halted":0,"volume":8897114,"delay":0,"changeRate":-0.0111,"floatShares":1341000000,"shares":1341000000,"eps":0.5962,"marketStatus":"已收盘","change":-0.11,"latestTime":"04-17 15:00:00","open":9.88,"high":9.89,"low":9.74,"amount":87122100,"amplitude":0.0151,"askPrice":9.82,"askSize":326,"bidPrice":9.81,"bidSize":27,"shortable":0,"etf":0,"ttmEps":0.5962,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776648600000},"marketStatusCode":5,"adr":0,"adjPreClose":9.92,"symbolType":"stock","openAndCloseTimeList":[[1776389400000,1776396600000],[1776402000000,1776409200000]],"highLimit":10.91,"lowLimit":8.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1341172692,"isCdr":false,"pbRate":0.95,"roa":"--","peRate":16.45421,"roe":"6.97%","epsLYR":0.7021,"committee":0.085513,"marketValue":13157000000,"turnoverRate":0.0066,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-20。","floatMarketCap":13157000000},"requestUrl":"/m/hq/s/600420/wiki","defaultTab":"wiki","newsList":[{"id":"2627233331","title":"国药现代（600420）披露为下属公司提供担保的进展公告，4月15日股价上涨1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627233331","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627233331?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:24","pubTimestamp":1776263054,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，国药现代报收于10.0元，较前一交易日上涨1.94%，最新总市值为134.12亿元。该股当日开盘9.87元，最高10.05元，最低9.79元，成交额达1.85亿元，换手率为1.39%。本次担保未提供反担保，属于前期董事会审议通过的担保额度范围内。截至公告日，公司及控股子公司累计对外担保总额为17,000.00万元，占公司最近一期经审计净资产的1.23%，无逾期担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500043202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","600420","BK0020","BK0239","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473457","title":"股市必读：国药现代（600420）4月13日收盘跌5.48%，主力净流入21.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627473457?lang=zh_cn&edition=full","pubTime":"2026-04-14 01:02","pubTimestamp":1776099733,"startTime":"0","endTime":"0","summary":"截至2026年4月13日收盘，国药现代报收于9.83元，下跌5.48%，换手率2.36%，成交量31.62万手，成交额3.09亿元。交易信息汇总4月13日国药现代收盘报9.83元，跌5.48%，当日成交3162.04万元。前10个交易日资金流向情况：主力资金累计净流出1.13亿元，股价累计下跌5.17%；融资余额累计增加340.21万元，融券余量累计增加1.38万股。4月13日主力资金净流入21.68万元，占总成交额0.07%；游资资金净流入1417.56万元，占总成交额4.59%；散户资金净流出1439.23万元，占总成交额4.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400000777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0020","600420","BK0132","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626122623","title":"每周股票复盘：国药现代（600420）一季度净利预盈1.26亿至1.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2626122623","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626122623?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:54","pubTimestamp":1775930053,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，国药现代报收于10.4元，较上周的10.54元下跌1.33%。本周，国药现代4月8日盘中最高价报10.68元。4月7日盘中最低价报10.29元。国药现代当前最新总市值139.48亿元，在化学制药板块市值排名38/150，在两市A股市值排名1470/5196。国药现代发布业绩预告，预计2026年1-3月扣非后净利润盈利1.34亿元至1.56亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0132","BK0082","BK0010","BK0239","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626198919","title":"国药现代(600420.SH)发预减，预计第一季度归母净利润1.26亿元到1.48亿元，同比下降65.03%到58.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626198919","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626198919?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:38","pubTimestamp":1775810281,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，公司预计2026年1-3月实现归属于上市公司股东的净利润1.26亿元到1.48亿元，同比下降65.03%到58.94%。2025年下半年以来，全球原料药产业面临本土化回流加速、印度及美国贸易保护主义加剧、国内抗生素产能过剩、集采政策持续传导以及部分核心客户需求下降等因素叠加影响，抗生素类医药中间体及原料药行业整体承压。面对严峻形势，公司主动以价换量争取市场份额，因价格下行导致医药中间体及原料药板块毛利率大幅下降，从上年同期的32.65%降至15.35%，导致本期归属于上市公司股东的净利润较上年同期下降幅度超过50%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"国药现代(600420.SH)发预减，预计第一季度归母净利润1.26亿元到1.48亿元，同比下降65.03%到58.94%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625939517","title":"国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，4月7日股价下跌0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625939517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625939517?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:29","pubTimestamp":1775554155,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，国药现代报收于10.51元，较前一交易日下跌0.28%，最新总市值为140.96亿元。该股当日开盘10.62元，最高10.63元，最低10.29元，成交额达1.14亿元，换手率为0.81%。近日，国药现代披露《关于全资子公司药品通过仿制药一致性评价的自愿性信息披露公告》。截至目前，国药金石对该产品的一致性评价累计研发投入约283万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","600420","BK0010","BK0239","BK0082","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624065502","title":"国药现代(600420.SH)：盐酸氨溴索片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2624065502","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624065502?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:47","pubTimestamp":1775206028,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)公告，公司全资子公司国药集团汕头金石制药有限公司(简称国药金石)收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准盐酸氨溴索片(30mg)通过仿制药质量和疗效一致性评价。盐酸氨溴索是新一代黏痰溶解剂，可以改善排痰，并具有促进肺表面活性物质和气道分泌及纤毛运动的作用。在临床上可以广泛用于伴有呼吸道异常分泌的急慢性呼吸道疾患，特别是慢性支气管炎的祛痰治疗，新生儿呼吸窘迫症以及肺部手术的辅助治疗，具有毒性低、疗效确切、并能与抗生素并用产生良好的协同效果等优点，为最常用的祛痰药之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：盐酸氨溴索片通过一致性评价","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0239","BK0132","BK0082","BK0010","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624655744","title":"国药现代(600420.SH)子公司获左卡尼汀注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624655744","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624655744?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:38","pubTimestamp":1775205533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)公告，公司控股子公司国药一心制药有限公司(简称国药一心)收到国家药品监督管理局核准签发的左卡尼汀注射液《药品注册证书》。左卡尼汀注射液适用于慢性肾衰长期血透病人因继发性肉碱缺乏产生的一系列并发症状，临床表现如心肌病、骨骼肌病、心律失常、高脂血症，以及低血压和透析中肌痉挛等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425087.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)子公司获左卡尼汀注射液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0132","BK0239","BK0082","BK0010","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623057350","title":"股市必读：国药现代年报 - 第四季度单季净利润同比增长8.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623057350","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623057350?lang=zh_cn&edition=full","pubTime":"2026-03-30 04:06","pubTimestamp":1774814773,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动截至2026年2月28日，公司股东户数为3.59万户，较2025年12月31日减少3026.0户，减幅7.78%；户均持股数量由上期的3.45万股上升至3.74万股，户均持股市值为39.97万元。业绩披露要点财务报告2025年公司主营收入93.63亿元，同比下降14.39%；归母净利润9.42亿元，同比下降13.11%；扣非净利润8.49亿元，同比下降18.6%。其中第四季度主营收入24.43亿元，同比上升4.2%；单季度归母净利润1.4亿元，同比上升8.78%；单季度扣非净利润1.1亿元，同比下降5.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000000871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854993","title":"国药现代(600420)2月28日股东户数3.59万户，较上期减少7.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854993","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622854993?lang=zh_cn&edition=full","pubTime":"2026-03-28 17:02","pubTimestamp":1774688570,"startTime":"0","endTime":"0","summary":"证券之星消息，近日国药现代披露，截至2026年2月28日公司股东户数为3.59万户，较12月31日减少3026.0户，减幅为7.78%。在化学制药行业个股中，国药现代股东户数高于行业平均水平，截至2月28日，化学制药行业平均股东户数为3.44万户。从股价来看，2025年12月31日至2026年2月28日，国药现代区间涨幅为5.84%，在此期间股东户数减少3026.0户，减幅为7.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032800021499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600420","BK0082","BK0020","BK0010","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622821984","title":"国药现代(600420.SH)发布2025年度业绩，归母净利润9.42亿元，同比下降13.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622821984","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622821984?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:42","pubTimestamp":1774615331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 披露2025年年度报告，报告期公司实现营收93.63亿元，同比下降14.39%;归母净利润9.42亿元，同比下降13.11%;扣非净利润8.49亿元，同比下降18.60%;基本每股收益0.7021元。报告期内，公司原料药及医药中间体板块实现销售收入44.76亿元，比上年同期下降13.89%，占本期营业收入的47.81%，比上年同期增加0.28个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"国药现代(600420.SH)发布2025年度业绩，归母净利润9.42亿元，同比下降13.11%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622231638","title":"国药现代拟每10股派发现金股利2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622231638","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622231638?lang=zh_cn&edition=full","pubTime":"2026-03-27 18:36","pubTimestamp":1774607760,"startTime":"0","endTime":"0","summary":"3月27日，国药现代（600420）发布公告，公司拟向全体股东每10股派发现金股利2元（含税），预计总派发金额为2.68亿元。2025年，国药现代实现收入93.63亿元，归母净利润9.42亿元。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-27/doc-inhsmnzs5319067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK0010","BK0082","600420","BK0239","VIG","BK4585","BK0020","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050234","title":"国药现代最新公告：控股子公司签署《药品上市许可转让合同》","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050234?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:10","pubTimestamp":1774343445,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司控股子公司国药致君与上海博悦签署《药品上市许可转让合同》，以1050万元受让其正在申报注册的盐酸乙哌立松片(50mg)上市许可及相关权益。该产品尚处于注册申报阶段，后续获批及持有人变更存在不确定性，对公司当期业绩无重大影响。此次交易有助于丰富公司骨骼肌肉系统用药产品线，增强子公司市场竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0010","BK0020","BK0239","BK0082","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616314634","title":"国药现代(600420.SH)：己酮可可碱注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616314634","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616314634?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:06","pubTimestamp":1772525197,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)公告，公司全资子公司国药集团容生制药有限公司(简称国药容生)收到国家药品监督管理局核准签发的己酮可可碱注射液《药品注册证书》。公告显示，己酮可可碱注射液主要适用于：外周动脉疾病(间歇性跛行或静息痛);内耳循环障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：己酮可可碱注射液获药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0020","BK0132","600420","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616584307","title":"每周股票复盘：国药现代（600420）全资孙公司获原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616584307","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616584307?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:31","pubTimestamp":1772303470,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，国药现代报收于10.69元，较上周的10.63元上涨0.56%。本周，国药现代2月25日盘中最高价报10.8元。国药现代当前最新总市值143.37亿元，在化学制药板块市值排名36/150，在两市A股市值排名1526/5189。本周关注点公司公告汇总：全资孙公司获盐酸米那普仑原料药上市批准，累计研发投入718.23万元。该原料药符合药品注册有关要求，批准注册。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","600420","BK0010","BK0239","BK0082","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613796206","title":"国药现代(600420.SH)：盐酸米那普仑获得化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613796206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613796206?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:02","pubTimestamp":1771923765,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 发布公告，近日，公司全资孙公司江苏威奇达药业有限公司收到国家药品监督管理局核准签发的关于原料药盐酸米那普仑的《化学原料药上市申请批准通知书》。盐酸米那普仑是由法国皮尔法伯公司研发推广的一种口服选择性5-羟色胺和去甲肾上腺素再吸收抑制剂，用于治疗重度抑郁症。上述事项不会对公司当期经营业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0082","BK0020","BK0132","BK0010","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610936167","title":"国药现代最新公告：公司及下属子公司51个药品拟中选国家集采药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936167","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610936167?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:59","pubTimestamp":1770807598,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司及下属子公司参加了国家集采药品第1-8批协议期满品种接续采购，合计51个药品拟中选。主要拟中选药品包括硝苯地平控释片、注射用甲泼尼龙琥珀酸钠、苯磺酸氨氯地平片、头孢呋辛酯片等。2024年度和2025年前三季度，这些药品的销售收入分别占公司同期营业收入的20.59%和23.15%。公司表示，中选结果有利于稳固现有市场份额，提升品牌影响力，但对当期经营业绩不会产生重大影响。最终中选情况、合同签订和市场销售执行等存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100031719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0010","BK0020","BK0082","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608070630","title":"每周股票复盘：国药现代（600420）2025年净利降12.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070630","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070630?lang=zh_cn&edition=full","pubTime":"2026-02-01 04:13","pubTimestamp":1769890389,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，国药现代报收于10.63元，较上周的10.59元上涨0.38%。业绩披露要点业绩快报国药现代近日即将发布2025年年报，根据1月26日发布的业绩快报，归属净利润盈利9.444亿元，同比减少12.85%。2025年度业绩快报上海现代制药股份有限公司发布2025年度业绩快报，营业总收入9,363,062,749.56元，同比下降14.40%；营业利润1,314,013,493.87元，同比下降25.00%；归属于上市公司股东的净利润944,379,815.55元，同比下降12.85%。本次计提减少公司2025年度合并报表利润总额13,395.59万元，上述数据未经审计。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0239","BK0132","BK0082","BK0010","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606192602","title":"国药现代发布2025年度业绩快报，盈利9.444亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606192602","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606192602?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:33","pubTimestamp":1769423590,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代近日即将发布2025年年报，根据1月26日发布的业绩快报，归属净利润盈利9.444亿元，同比减少12.85%。以上综合因素导致公司报告期内盈利水平下滑。国药现代主营业务：医药产品研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025773.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600420","BK0020","BK0239","BK0082","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605650405","title":"国药现代：公司积极推进缓控释、膜剂等创新技术平台建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2605650405","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605650405?lang=zh_cn&edition=full","pubTime":"2026-01-23 21:40","pubTimestamp":1769175600,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月23日，国药现代在互动平台回答投资者提问时表示，公司始终坚持“科技引领，创新驱动”策略，加速科技创新步伐，进一步推动改良型新药和高端复杂制剂的布局，积极推进缓控释、膜剂等创新技术平台建设。合成生物学领域，主要与华东理工大学等高等院校开展有关项目的研究合作。有关公司研发具体情况，以公司披露的年度报告有关章节内容为准。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-23/doc-inhiicfu0914802.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-23/doc-inhiicfu0914802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0010","BK0082","600420","BK0239","BK0020","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604923561","title":"每周股票复盘：国药现代（600420）注射用哌拉西林钠通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923561","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923561?lang=zh_cn&edition=full","pubTime":"2026-01-18 02:37","pubTimestamp":1768675027,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，国药现代报收于10.63元，较上周的10.59元上涨0.38%。本周关注点公司公告汇总：注射用哌拉西林钠新增1.0g规格获批并通过一致性评价。公司公告汇总上海现代制药股份有限公司全资子公司国药集团威奇达药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准注射用哌拉西林钠新增1.0g规格，并通过0.5g、1.0g、2.0g规格的仿制药质量和疗效一致性评价。截至目前，国药威奇达为此累计研发投入约612万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0010","BK0132","BK0020","BK0082","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776520558608,"stockEarnings":[{"period":"1week","weight":-0.0567},{"period":"1month","weight":-0.0866},{"period":"3month","weight":-0.0771},{"period":"6month","weight":-0.0806},{"period":"1year","weight":-0.0029},{"period":"ytd","weight":-0.0287}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.0123},{"period":"6month","weight":0.0551},{"period":"1year","weight":0.2351},{"period":"ytd","weight":0.0208}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海现代制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35868人(较上一季度减少7.78%)","perCapita":"37391股","listingDate":"2004-06-16","address":"上海市浦东新区建陆路378号","registeredCapital":"134117万元","survey":" 上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是6-APA、7-ACA、D-7ACA、青霉素工业钾盐、头孢曲松钠粗盐、氨苄西林酸。在制剂产品方面，根据米内网数据库显示，公司头孢呋辛酯片、注射用甲泼尼龙琥珀酸钠国内市场占有率稳居行业第一；头孢克肟颗粒市场份额进一步提升，展现出良好的增长态势；硝苯地平控释片、盐酸米那普仑片市场占有率稳居仿制药企业第一。","listedPrice":8.08},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药现代,600420,国药现代股票,国药现代股票老虎,国药现代股票老虎国际,国药现代行情,国药现代股票行情,国药现代股价,国药现代股市,国药现代股票价格,国药现代股票交易,国药现代股票购买,国药现代股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}